PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Multiple Dose Study Of PF-05161704 In Healthy Volunteers
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PF-05161704 or Placebo
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT01202266
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 615
- Registration Number
- NCT01200407
- Locations
- π΅π
Private Clinic, Tuguegarao City, Philippines
π΅πMetropolitan Medical Center Institutional Review Board, Manila, Philippines
π΅πPines City Doctors Hospital, Baguio, Philippines
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT01200394
- Locations
- πΊπΈ
North America Research Institute, Azusa, California, United States
πΊπΈCalifornia Kidney Specialists, San Dimas, California, United States
πΊπΈResearch Across America, Houston, Texas, United States
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
- Conditions
- Healthy Subjects
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)Biological: 7-valent pneumococcal conjugate vaccine (7vPnC)Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)Biological: DTaP
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 551
- Registration Number
- NCT01200368
- Locations
- π―π΅
National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan
π―π΅Harada Clinic, Fukuoka, Japan
π―π΅Childrens Clinic of Kose, Kofu, Yamanashi, Japan
Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01199900
- Locations
- πΊπΈ
Pfizer Investigational Site, Kalamazoo, Michigan, United States
Effect of Prevnar 13 on Ear Infections in Children
- Conditions
- Otitis Media
- Interventions
- Procedure: TympanocentesisProcedure: Nose/throat swabBiological: Observational
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 239
- Registration Number
- NCT01199016
- Locations
- πΊπΈ
Penfield Pediatrics, Penfield, New York, United States
πΊπΈLong Pond Pediatrics, Rochester, New York, United States
πΊπΈPathway Pediatrics, Rochester, New York, United States
Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01199029
- Locations
- πΊπΈ
Pfizer Investigational Site, Kalamazoo, Michigan, United States
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: AAB-003 (PF-05236812)Other: Placebo
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT01193608
- Locations
- πΊπΈ
Atlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈBelmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States
πΊπΈFoers Medical Arts Pharmacy, Bethesda, Maryland, United States
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevenar
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 505
- Registration Number
- NCT01193582
- Locations
- π¨π³
Baolixiang Clinic, Baoli Town,Yongfu County, Guangxi, China
π¨π³Luojin Clinic, Luojin Town, Yongfu County, Guangxi, China
π¨π³Guangfuxiang Clinic, Guangfu Town, Yongfu County, Guangxi, China
Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01193062
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States